Pyrazide
Pyrazine-2-carboxamide
Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 1046.
Registration
- Applicants
- 1
- Registrations
- 1
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Sanofi-aventis South Africa (Pty) Ltd | Pyrazide | tablets | A0095 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Pyrazide tablets EACH TABLET CONTAINS PYRAZINAMIDE A 500,0 mg | Tablets | A0095 | Old Medicine | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Pyrazinamide
Consolidated Schedules 06 July 2026, line 7685
S3: Pyrazinamide
- when intended for oral use.
Consolidated Schedules 06 July 2026, line 4189
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.